Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 16/20 | 0.60 |
| ▸ | MMP2 | P08253 | 14/20 | 0.60 |
| ▸ | MMP1 | P03956 | 12/20 | 0.60 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7412150 | 0.90 | MMP13 (0.60) | MMP13MMP2MMP1MMP9MMP7 | |
| SCHEMBL6087288 | 0.88 | MMP2 (0.67) | MMP13MMP2MMP1MMP9 | |
| SCHEMBL7416696 | 0.78 | MMP13 (0.67) | MMP13MMP2MMP1MMP9MMP7 | |
| SCHEMBL6809658 | 0.75 | MMP13 (0.50) | MMP13MMP2MMP1MMP9NPSR1 | |
| SCHEMBL16839866 | 0.68 | LTA4H (0.52) | NPSR1 | |
| SCHEMBL7210912 | 0.67 | MMP1 (0.51) | MMP13MMP2MMP1MMP9 | |
| SCHEMBL4652358 | 0.67 | MMP1 (1.00) | MMP13MMP2MMP1MMP9 | |
| SCHEMBL7344377 | 0.67 | SMN1; SMN2 (0.48) | MMP13MMP2MMP1MMP9NPSR1 | |
| SCHEMBL25061922 | 0.67 | KMT2A (0.73) | NPSR1SMN1; SMN2 | |
| SCHEMBL6767568 | 0.66 | MMP13 (0.77) | MMP13MMP2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417229-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-07-09 | — | — | US | claimed |
| EP-1088550-A1 | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| EP-1088550-A1 | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |